| 27th week of 2012 patent applcation highlights part 52 |
| Patent application number | Title | Published |
|---|
| 20120172378 | NOVEL COMPOUNDS - Pyrimidone compounds of formula (I): | 2012-07-05 |
| 20120172379 | 4 SUBSTITUTED PYRAZOLOPYRIMIDINES - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. | 2012-07-05 |
| 20120172380 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT - The invention relates to substituted 4-(tetrazol-5-yl)-quinazoline derivatives of the formula-I, | 2012-07-05 |
| 20120172381 | Tricyclic Compounds as Modulators of TNF-alpha Synthesis and as PDE4 Inhibitors - The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-α or by PDE4, including but not limited to rheumatoid arthritis. | 2012-07-05 |
| 20120172382 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES - Compounds useful in the treatment of mammalian cancers and especially human cancers according to Formula I are disclosed. | 2012-07-05 |
| 20120172383 | FUNGICIDAL COMPOSITIONS BASED ON PYRIDYLMETHYLBENZAMIDE DERIVATIVES AND AT LEAST ONE COMPLEX III INHIBITING COMPOUND - 1) Fungicidal compositions comprising: a) at least one pyridylmethylbenzamide derivative of Formula (I), in which the various radicals are as defined in the description; and b) at least one compound (II) capable of inhibiting the transport of electrons of the respiratory chain of mitochondrial ubiquinol:ferricytochrome-c oxidoreductase or complex III in phytopathogenic fungal organisms. 2) Process for curatively or preventively controlling the phytopathogenic fungi of crops, characterized in that an effective and nonphytotoxic quantity of one of these fungicidal compositions is applied to the aerial parts of plants. | 2012-07-05 |
| 20120172384 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS - The invention relates to compounds of formula (I) | 2012-07-05 |
| 20120172385 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS - The invention relates to compounds of formula (I) | 2012-07-05 |
| 20120172386 | Combinations Comprising a VEGF Receptor Inhibitor - A composition comprising a VEGF receptor inhibitor and a penetration enhancer and uses thereof. | 2012-07-05 |
| 20120172388 | Enhancement of Impaired Motor and Mental Functions, Using Dextromethorphan and Oxidase Enzyme Inhibitor - During clinical trials on patients suffering from neurological disorders, it has been observed that some patients obtain dramatic improvements in motor control and/or higher mental functioning, when they receive a combination of dextromethorphan and quinidine, at suitable dosages. Improved motor control has been exemplified to date by improved ability to swallow and/or speak, among victims of stroke, head injury, or ALS. Improved higher mental functioning has been exemplified in better job performance, increased ability to analyze and solve problems, and increased ability to have successful and satisfying interactions with other people. These types of effects can be seen in a relatively brief time period, such as within several days to a week. | 2012-07-05 |
| 20120172389 | TREATMENT OF FIBROSING DISORDERS - A method for treating liver-associated fibrosing disorders or lupus, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula | 2012-07-05 |
| 20120172390 | METHOD OF TREATING SLEEP DISORDERS USING THE COMBINATION OF EPLIVANSERIN AND ZOLPIDEM - The instant invention relates to a method of treating sleep disorders by using eplivanserin or pharmaceutically acceptable salts or esters thereof and Zolpidem by evaluating the effect of eplivanserin combined with the sleep-inducing agent Zolpidem on psychomotor/cognitive performance. | 2012-07-05 |
| 20120172391 | NAPHTHYRIDINONE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS - In one aspect, the invention relates to naphthyridinone analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2012-07-05 |
| 20120172392 | AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES - Compositions and methods are disclosed for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1). The compounds disclosed are amine-containing and amide-containing compounds. The compounds and compositions are useful for treatment of diseases, including inflammation, inflammatory diseases and autoimmune disorders. | 2012-07-05 |
| 20120172393 | (4-Phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone Compounds and Their Use - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. | 2012-07-05 |
| 20120172394 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RHEUMATOID ARTHRITIS, CONTAINING REBAMIPIDE - The present invention provides a pharmaceutical composition for preventing or treating rheumatoid arthritis comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier. The pharmaceutical composition may be for oral administration, for example an oral solid dosage form of a tablet or capsule form. The pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg. | 2012-07-05 |
| 20120172395 | SLOW-RELEASE CILOSTAZOL TABLET HAVING AN IMPROVED ELUTION RATE AND MINIMAL SIDE EFFECTS - Provided is a slow-release tablet including cilostazol as a pharmacologically active component, which is efficacious in suppressing aggregation of blood platelets and promoting vascular relaxation by inhibiting phosphodiesterase types. The slow-release cilostazol tablet has an extended elution time so that the slow-release cilostazol tablet can be taken once daily for convenience of drug use, and minimizes the manifestation of headache which is one side effect caused when women, the elderly and children take conventional cilostazol preparations so that the convenience of drug use can be improved. Also, the slow-release cilostazol tablet exhibits a stable elution pattern with no variation in elution rate according to changes in pH in the stomach and intestines, as well as an effect of delaying the release of a drug, using a mixture of hydroxypropyl methylcellulose and a carbomer as a release-controlling polymer. | 2012-07-05 |
| 20120172396 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS - The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions. | 2012-07-05 |
| 20120172397 | HEXAHYDROCYCLOPENTA[f]INDAZOLE 5-YL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS - The present invention encompasses compounds of Formula (I) or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included. | 2012-07-05 |
| 20120172398 | CO-CRYSTALS OF TRAMADOL AND COXIBS - The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses in pharmaceutical formulations for the treatment of pain. | 2012-07-05 |
| 20120172399 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF - This invention relates to new compounds that can serve as hypoxia mimetics. This invention also relates to methods of increasing HIF levels or activity in a subject or treating a condition associated with HIF levels or activity in a subject by administering to the subject at least one of these compounds. | 2012-07-05 |
| 20120172400 | SULFONAMIDES WITH HETEROCYCLE AND OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS - The invention relates to Sulfonamides with heterocycle and oxadiazolone headgroup and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARalpha agonist activity. What is described are compounds of the formula (I), in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system. | 2012-07-05 |
| 20120172401 | BENZIMIDAZOLE DERIVATIVE AND USE AS ANGIOTENSIN II ANTAGONIST - The present invention provides (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-cyclopropyl-1-{[2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate represented by the formula: | 2012-07-05 |
| 20120172402 | INDUCTION OF ALPHA HELIX CONFORMATIONS IN PROTEINS AND PEPTIDES - Substituted tricyclic diproline analogues of the formula (I): | 2012-07-05 |
| 20120172403 | LOW TEMPERATURE STABLE SOLUTION - This invention relates to liquid concentrates of 4,5-dichloro-2-(n-octyl-4-isothiazolin-3-one) (“DCOIT”) which are stable to crystallization or freezing at sub-freezing temperatures. | 2012-07-05 |
| 20120172404 | ANTIMICROBIALLY EFFECTIVE USE SOLUTIONS COMPRISING COMBINATIONS OF ISOTHIAZOLONES AND AMINES - The invention relates to a microbicidal use solution which comprises a) one or more isothiazolin-3-ones and b) one or two organic amines selected from N-dodecylpropane-1,3-diamine and bis(aminopropyl)-dodecylamine and optionally c) one or more oxidizing agents. The use solution is preferably in the form of technical and domestic products. | 2012-07-05 |
| 20120172405 | POLYMORPHIC FORMS OF 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACE- TIC ACID AND USES THEREOF - Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented. | 2012-07-05 |
| 20120172406 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF - The present invention relates to novel substituted thioimidazolidinone compounds and pharmaceutical compositions comprising such compounds for treatment of androgen receptor-associated diseases or disorders, such as prostate cancer, benign prostatic hypertrophy, male hair loss, muscle loss, acne and hirsutism. | 2012-07-05 |
| 20120172407 | N-ALKOXYCARBOXAMIDES AND THEIR USE AS MICROBIOCIDES - Compounds of formula (I) in which the substituents are as defined in claim | 2012-07-05 |
| 20120172408 | ACTIVE INGREDIENT COMPRISING INDOCYANINE GREEN AND/OR INFRACYANINE GREEN - The present invention relates to an active ingredient including indocyanine green and/or infracyanine green for use in treating dental or periodontal infectious diseases under irradiation with light, more particularly laser light, from a wavelength range between 790 nm and 830 nm. | 2012-07-05 |
| 20120172409 | METHODS AND KITS FOR LINKING POLYMORPHIC SEQUENCES TO EXPANDED REPEAT MUTATIONS - Methods and kits are provided for determining which single nucleotide polymorphism (“SNP”) variant of an allele of a heterozygous patient is on the same allele as a disease-causing mutation. Also, provided are kits for multi-SNP diagnosis and treatment, targeting combinations of SNPs having greater joint prevalence of heterozygosity in Huntington's population than individual SNPs considered individually. | 2012-07-05 |
| 20120172410 | SHORT HAIRPIN RNA FOR GENE KNOCKDOWN OF NR1 SUBUNIT OF THE N-METHYL-D-ASPARTATE RECEPTOR AND ITS APPLICATION ON PHARMACEUTICS - A short hairpin RNA (shRNA) for gene knockdown the genetic expression of NR1 subunit of N-methyl-D-aspartate (NMDA) receptor comprises a first fragment sharing homologous nucleotides among the NR1 subunit of NMDA receptor; a second fragment having complementary sequence to the first fragment; and a connecting fragment having any base in repeated arrangement, and connecting to the first and second fragments. Also, a method of treatment for pathological pain, by applying the shRNA described above to subcutaneous tissues of living organisms for gene knockdown the genetic expression of the NR1 subunit of NMDA receptor in hypoderm. | 2012-07-05 |
| 20120172411 | NOVEL TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF - The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art. | 2012-07-05 |
| 20120172412 | In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages - The present invention is directed compositions for delivery of RNA interference (RNAi) polynucleotides to cells in vivo. The compositions comprise amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or DPC) are further covalently linked to an RNAi polynucleotide or co-administered with a targeted RNAi polynucleotide-targeting molecule conjugate. | 2012-07-05 |
| 20120172413 | INCREASING LIFESPAN BY MODULATING CRTC EXPRESSION OR LOCALIZATION, AND METHODS OF SCREENING FOR MODULATORS OF SAME - The invention relates to the field of longevity enhancement. More particularly, the invention provides compositions and methods relating to CRTC modulation. In certain embodiments, the invention provides compositions and methods for enhancing longevity in an organism by inhibiting CRTC activity, such as, for example, inhibiting CRTC expression or cellular localization in the organism. | 2012-07-05 |
| 20120172414 | BICYCLIC CYCLOHEXOSE NUCLEIC ACID ANALOGS - The present invention provides bicyclic cyclohexose nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. These bicyclic nucleoside analogs are useful for enhancing properties of oligomeric compounds including nuclease resistance. | 2012-07-05 |
| 20120172415 | Exon Skipping Therapy for Functional Amelioration of Semifunctional Dystrophin in Becker and Duchenne Muscular Dystrophy - Methods for stabilizing unstable proteins or for restoring functionality to non-functional or poorly functioning (semi-functional) proteins using exon skipping technology are provided. The methods involve the administration of antisense oligonucleotides to cause exon skipping, thereby removing one or more exons responsible for protein instability or lack of functionality. For example, exons encoding protease recognition sites may be removed. The method is useful for treating diseases caused by protein instability, such as Becker Muscular Dystrophy, or for treating Duchenne Muscular Distrophy patients with semi-functional dystrophin due to treatment with other exon skipping or stop codon readthrough therapies. | 2012-07-05 |
| 20120172416 | METHOD FOR THE PREPARATION OF MICRO-RNA AND ITS THERAPEUTIC APPLICATION - The present invention relates to compositions comprising a therapeutically effective amount of miRNAs, their use for the treatment of medical conditions benefiting from being treated with these compositions, as well as methods for the preparation of compositions comprising miRNAs. | 2012-07-05 |
| 20120172417 | System And Method For Identifying And Applying Peripheral Treatment Mechanisms For Disease - A method and system for the identification and application of biological targets for peripheral treatment of diseases. Existing cellular mechanisms or pathways are exploited to identify novel genes or other molecule candidates that will be used to treat disease via a peripheral treatment system. Using the method, a novel Alzheimer's disease target is identified and used to treat an animal Alzheimer's disease model via peripheral expression of that target. | 2012-07-05 |
| 20120172418 | ASLV VECTOR SYSTEM - The invention provides a viral self-inactivating (SIN) vector on the basis of the avian sarcoma leukosis virus (ASLV) as well as a split-packaging system comprising in addition to the SIN vector a first helper plasmid serving for the expression of the viral fusion protein gag-pol and a second helper plasmid serving for the expression of the retroviral envelope protein (env). The first and second helper plasmid, for example contained in a packaging cell line or transiently transfected, serve for the generation of non-replicating (RCR-incompetent) viral particles containing RNA having a SIN LTR according to the invention at the 3′ terminus, wherein the RNA can have a therapeutically effective section which e.g. is denoted a transgene. This 3′ SIN LTR contains an extensive deletion of the U3 region which in the course of the reverse transcription is copied into the 5′ LTR. In addition, in the SIN vector all coding regions of ASLV as well as the retroviral splice donor site are removed. | 2012-07-05 |
| 20120172419 | REAGENTS AND METHODS FOR MODULATING CONE PHOTORECEPTOR ACTIVITY - The present invention provides reagents and methods for modulating cone photoreceptor activity, and devices for assessment of cone photoreceptor activity. | 2012-07-05 |
| 20120172420 | Method for Modulating Responsiveness to Steroids - A method for enhancing steroid efficacy in a steroid refractory patient afflicted with an inflammatory condition not responding or responding poorly or inadequately to anti-inflammatory treatment comprises administering an oligonucleotide having the sequence formula | 2012-07-05 |
| 20120172421 | 2, 6 XYLIDINE DERIVATIVES FOR THE TREATMENT OF PAIN - The disclosure herein provides a compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1. The compound of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof may be formulated as pharmaceutical composition. The pharmaceutical composition of compound of formula 1 or the final compound may be formulated for non-invasive peroral, topical (example transdermal), enteral, transmucosal, targeted delivery, sustained release delivery, delayed release, pulsed release and parenteral methods. Such compositions may be used to treat chronic pain manifested with chronic diseases or its associated complications. The compound may also be offered as a kit. | 2012-07-05 |
| 20120172422 | Methods of Treatment Using a Prodrug of an Excitatory Amino Acid - This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders. | 2012-07-05 |
| 20120172423 | COMPOSITIONS AND METHODS FOR TREATING HERPES SIMPLEX VIRUS - Green tea polyphenol compositions and methods of their use in treating herpes simplex virus (HSV) are provided. Representative green tea polyphenols include, but are not limited to (−)-epigallocatechin-3-gallate as well as green tea polyphenols with one on more ester-linked fatty acids. | 2012-07-05 |
| 20120172424 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY - Novel chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described. | 2012-07-05 |
| 20120172425 | RED YEAST RICE EXTRACT HIGH IN MONACOLIN K CONTENT - Compositions comprising Red Yeast Rice extracts which comprise greater than 5 wt. % monacolin K are useful for lowering cholesterol and/or triglyceride levels in a subject. | 2012-07-05 |
| 20120172426 | Compositions, Synthesis, and Methods of Using Cycloalkylmethylamine Derivatives - The present invention provides novel cycloalkylmethylamine derivatives, and methods of preparing cycloalkylmethylamine derivatives. The present invention also provides methods of using cycloalkylmethylamine derivatives and compositions of cycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications. | 2012-07-05 |
| 20120172427 | (Z)-2-CYANO-3-HYDROXY-BUT-2-ENOIC ACID-(4'-TRIFLUOROMETHYLPHENYL)-AMIDE TABLET FORMULATIONS WITH IMPROVED STABILITY - The invention relates to solid pharmaceutical compositions comprising (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide, as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from autoimmune diseases in particular systemic lupus erythematosus or chronic graft-versus-host disease, multiple sclerosis or rheumatoid arthritis. | 2012-07-05 |
| 20120172428 | Novel Formulations of Bifenthrin and Enriched Cypermethrin - The present invention is directed to novel insecticidal compositions comprising bifenthrin and enriched cypermethrin, the compositions are physically stable when diluted with water. | 2012-07-05 |
| 20120172429 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI- INFLAMMATORY AGENTS - The invention provides compounds, compositions, methods, and kits for the treatment of neurogenic inflammation. | 2012-07-05 |
| 20120172430 | COMPOSITIONS OF DIBROMOMALONAMIDE AND THEIR USE AS BIOCIDES - A biocidal composition comprising 2,2-dibromomalonamide and 2,2-dibromo-3-nitrilopropionamide, and its use for the control of microorganisms in aqueous and water-containing systems. | 2012-07-05 |
| 20120172431 | OMEGA 3 FATTY ACID FORMULATIONS - The present invention provides highly purified omega-3 fatty acid formulations. Certain formulations provided herein have contain greater than 85% omega-3 fatty acids by weight. Certain other formulations provided herein contain EPA and DHA in a ratio of from about 4.01:1 to about 5:1. The invention also provides methods of using the dosage forms to treat a variety of cardiovascular, autoimmune, inflammatory, and central nervous system disorders by administering a formulation of the invention to a patient in need thereof. | 2012-07-05 |
| 20120172432 | PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND A CARDIOVASCULAR AGENT AND METHODS OF USING THE SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same. | 2012-07-05 |
| 20120172433 | Oil-In-Water Emulsion Skin Care Cosmetic Composition - To provide an oil-in-water emulsion skin care cosmetic composition which, without the addition of a pharmaceutical agent and a film-forming agent or the like thereto, effects an excellent elastic or resilient feeling to skin and is excellent in non-stickiness and stability. An oil-in-water emulsion skin care cosmetic composition, comprising (a) a paraffin wax and/or a polyethylene wax, (b) a microcrystalline wax, and (c) an animal/plant-derived wax which contains, as the main ingredient thereof, an ester of a higher fatty acid having from 20 to 32 carbon atoms and an alcohol having from 28 to 34 carbon atoms, and has a melting point of from 75 to 100° C., in which the ratio of component (a) to component (b) is from 70/30 to 95/5 (by mass). | 2012-07-05 |
| 20120172434 | METHODS FOR IMPROVING TOLERANCE, DIGESTION, AND LIPID SOLUBLE NUTRIENT ABSORPTION IN AN INFANT, TODDLER, OR CHILD - Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid component. | 2012-07-05 |
| 20120172435 | METHODS FOR TREATING ACUTE ACOUSTIC TRAUMA - The current invention provides methods and compositions for treating sensorineural hearing loss including but not limited to acute acoustic trauma (AAT). The composition 2,4-disulfonyl α-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC). Preferably, the compositions for treating AAT will be administered orally. However, other methods which deliver the compositions for treating AAT systemically to the body should work equally well. | 2012-07-05 |
| 20120172436 | Liver Regeneration Accelerator Comprising Betaine - The present invention relates to betaine or a composition comprising the same for accelerating liver regeneration, more particularly, a therapeutic pharmaceutical composition comprising betaine represented by formula 1 as an active ingredient for promoting the recovery of injured or resected liver to the normal liver. The most effective treatment for chronic liver disease, particularly in the terminal stage, is hepatectomy and liver transplantation. In Living Donor Liver Transplantation (LDLT) that has been increasing since 1990, rapid regeneration of liver tissues is essential for both donor and recipient to inhibit complications and thus for the success of the treatment. Betaine accelerates the recovery and growth of injured liver to the normal liver, so that it can be effectively used for the successful LDLT or therapeutic hepatectomy. | 2012-07-05 |
| 20120172437 | CONTINUOUS ON-LINE ADJUSTABLE DISINFECTANT/SANITIZER/BLEACH GENERATOR - Methods and systems for on-site, continuous generation of peracid chemistry, namely peroxycarboxylic acids and peroxycarboxylic acid forming compositions, are disclosed. In particular, an adjustable biocide formulator or generator system is designed for on-site generation of peroxycarboxylic acids and peroxycarboxylic acid forming compositions from sugar esters. Methods of using the in situ generated peroxycarboxylic acids and peroxycarboxylic acid forming compositions are also disclosed. | 2012-07-05 |
| 20120172438 | GLYCYRRHETINIC ACID ESTER DERIVATIVE SYNTHESIS METHOD AND DEOXOGLYCYRRHETINIC ACID ESTER COMPOUND - A compound represented by formula II, a preparation method, and uses thereof in treating liver damage and inflammation and so on are disclosed. A method for preparing glycyrrhetinic acid derivatives are also disclosed. In the compound represented by formula II, R | 2012-07-05 |
| 20120172439 | GENERATION OF PEROXYCARBOXYLIC ACIDS AT ALKALINE pH, AND THEIR USE AS TEXTILE BLEACHING AND ANTIMICROBIAL AGENTS - The present disclosure provides methods for generating percarboxylic acid compositions and/or peroxycarboxylic acid compositions formed external to a point of use in non-equilibrium reactions for use in certain bleaching and antimicrobial applications, in particular laundry applications. The compositions are generated external to a point of use, at alkaline pH levels, viz. greater than about pH 12, and optionally suitable for use with detergents and/or surfactants for synergistic bleaching efficacy. Methods of bleaching and/or disinfecting are further provided. | 2012-07-05 |
| 20120172440 | IN SITU GENERATION OF PEROXYCARBOXYLIC ACIDS AT ALKALINE pH, AND METHODS OF USE THEREOF - The present disclosure is related to percarboxylic acid compositions formed in situ in non-equilibrium reactions. The peroxycarboxylic acid compositions are formed using ester based starting materials. Methods for using the percarboxylic acid compositions are also disclosed. | 2012-07-05 |
| 20120172441 | IN SITU GENERATION OF PEROXYCARBOXYLIC ACIDS AT ALKALINE pH, AND METHODS OF USE THEREOF - The present disclosure is related to percarboxylic acid compositions formed in situ in non-equilibrium reactions. The peroxycarboxylic acid compositions are formed using ester based starting materials. Methods for using the percarboxylic acid compositions are also disclosed. | 2012-07-05 |
| 20120172442 | METHODS FOR DECREASING THE INCIDENCE OF NECROTIZING ENTEROCOLITIS, COLIC, AND SHORT BOWEL SYNDROME IN AN INFANT, TODDLER, OR CHILD - Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid component. | 2012-07-05 |
| 20120172443 | NUTRITIONAL PRODUCTS INCLUDING A NOVEL FAT SYSTEM INCLUDING MONOGLYCERIDES - Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid component. | 2012-07-05 |
| 20120172444 | Use of Conjugated Linoleic Acid - Conjugated linoleic acid (CLA) or a derivative thereof may be used in reducing the rate of increase of fat mass in a growing child. | 2012-07-05 |
| 20120172445 | NUTRITIONAL PRODUCTS INCLUDING A NOVEL FAT SYSTEM INCLUDING FATTY ACIDS - Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid component. | 2012-07-05 |
| 20120172446 | L-SERINE TO BE USED AS A DRUG FOR PREVENTING AND/OR TREATING AN INFLAMMATORY RESPONSE OF THE SKIN - The invention relates to the use of L-serine as a drug for preventing and/or treating an inflammatory response of the skin caused by the overexpression and/or the overactivation of PAR2 receptors. | 2012-07-05 |
| 20120172447 | COMPOSITION COMPRISING VITAMIN U AS ACTIVE INGREDIENT FOR HEALING SKIN WOUND - Disclosed is a composition comprising vitamin U as an active ingredient, more precisely a composition for repairing the skin wound that contains vitamin U as an active ingredient. The composition demonstrates excellent wound healing and skin wound repairing effects. | 2012-07-05 |
| 20120172448 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof - The present application relates to novel substituted 1-benzylcycloalkylcarboxylic acid derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders. | 2012-07-05 |
| 20120172449 | POLYAMINE TRANSPORT INHIBITORS AS NOVEL THERAPEUTICS - Novel polyamine transport inhibitors have been synthesized and demonstrated to block the uptake of native polyamines into human cancer cells. A combination therapy of the transport inhibitor and DFMO (a drug which blocks polyamine biosynthesis) provided synergistic activity against a metastatic human colon cancer cell line. The strategy uses polyamine depletion and polyamine metabolism to generate reactive oxygen species within cells as a novel way to treat cancers. This approach may be implemented for widespread use in the treatment of diseases which rely upon polyamine transport activity for proliferation. | 2012-07-05 |
| 20120172450 | USE OF JASMONATE FOR IMPROVING SKELETAL MUSCLE FUNCTION - A formulation comprising jasmonate for improving skeletal muscle function in a mammal, particularly a human is provided. This may be accomplished by reducing muscle fatigue and/or increasing skeletal muscle performance. | 2012-07-05 |
| 20120172451 | CLEANING LIQUID - The present invention relates to a cleaning fluid, in particular a cleaning fluid for cleaning surfaces. | 2012-07-05 |
| 20120172452 | TOPICAL NITRONE SPIN TRAP COMPOSITIONS FOR PSORIASIS - Psoriasis is treated by application of a composition containing a nitrone spin trap such as α-phenyl t-butyl nitrone (PBN) and derivatives thereof. Preferred compositions and method of treatments further comprise at least one adjunctive ingredient including fatty acid esters of ascorbic acid such as ascorbyl palmitate and ascorbyl stearate, and polyenylphosphatidylcholine. | 2012-07-05 |
| 20120172453 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES - This invention relates to the 5-cis and 5-trans isomers of geranylgeranyl acetone, preferably such synthetic isomers, and pharmaceutical compositions containing such isomers. Other aspects of this invention relate to the use of geranylgeranyl acetone and its isomers in methods for inhibiting neural death, increasing neural activity, and increasing axon growth and cell viability. Geranylgeranyl acetone is a known anti-ulcer drug used commercially and in clinical situations. GGA has also been shown to exert cytoprotective effects on a variety of organs, such as the eye, brain, and heart. | 2012-07-05 |
| 20120172454 | BIODEGRADABLE DRUG DELIVERY COMPOSITIONS - A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as a pharmaceutically active principle is disclosed. | 2012-07-05 |
| 20120172455 | Functionalized water-soluble polyphosphazenes and uses thereof as modifiers of biological agents - A polyphosphazene polymer which includes hydrophilic side groups and interacting side groups which are capable of bonding with a biological agent of interest. The bonding may be by non-covalent bonding. | 2012-07-05 |
| 20120172456 | ENGINEERED MICROPARTICLES FOR MACROMOLECULE DELIVERY - A method for making a modified release composition, comprising:
| 2012-07-05 |
| 20120172457 | NOVEL POWDERED POLYMER, PREPARATION METHOD THEREOF AND USE OF SAME AS A THICKENER - Disclosed is a branched or crosslinked anionic polyelectrolyte of at least one monomer having a partially- or totally-salified strong acid function, with at least one neutral monomer and at least one monomer having formula (I), wherein: R represents a linear or branched alkyl radical including between 8 and twenty carbon atoms, and n represents a number greater than or equal to 1 and less than or equal to twenty. Also described is the use thereof as a thickener in topical compositions. | 2012-07-05 |
| 20120172458 | HYDROCARBON SYNTHESIS REACTION APPARATUS, HYDROCARBON SYNTHESIS REACTION SYSTEM, AND LIQUID HYDROCARBON RECOVERY METHOD - A hydrocarbon synthesis reaction apparatus synthesizes hydrocarbons by a Fischer-Tropsch synthesis reaction. The apparatus includes a reactor; a flowing line; a first cooling unit; a second cooling unit; a first separating unit which separates the liquid hydrocarbons condensed by the first cooling unit from the gaseous hydrocarbons; and a second separating unit which separates the liquid hydrocarbons condensed by the second cooling unit from the gaseous hydrocarbons. The first cooling unit cools the hydrocarbons which flow through the flowing line to a temperature range equal to or lower than a condensing point at which a wax fraction condenses, and higher than a freezing point at which the wax fraction solidifies. The second cooling unit cools the hydrocarbons which flow through the flowing line to a temperature range lower than the temperature to which the gaseous hydrocarbons are cooled by the first cooling unit, and higher than a freezing point at which a middle distillate solidifies. | 2012-07-05 |
| 20120172459 | Acetylene Enhanced Conversion of Syngas to Fischer-Tropsch Hydrocarbon Products - A method is disclosed for converting syngas to Fischer-Tropsch (F-T) hydrocarbon products. A synthesis gas including carbon monoxide and hydrogen gas is provided to a F-T reactor. Also, acetylene is supplied to the F-T reactor. The ratio of the volume of acetylene to the volume of synthesis gas is at least 0.01. The synthesis gas and acetylene are reacted under suitable reaction conditions and in the presence of a catalyst to produce F-T hydrocarbon products. The F-T hydrocarbon products are then recovered from the reactor. The synthesis gas and acetylene may be provided in a combined feed stream or introduced separately into the reactor. The acetylene enhanced syngas conversion in a F-T reactor results in the synthesis of F-T products which have a tighter distribution of intermediate length carbon products than do F-T products synthesized according to conventional methods. | 2012-07-05 |
| 20120172460 | PROCESS FOR PRODUCING SYNTHETIC HYDROCARBONS FROM CARBONACEOUS MATERIALS EXCHANGER - A method for producing synthetic hydrocarbons from at least one carbonaceous material is provided. The method includes evaluating the resources of the carbonaceous material available on a determined territory; determining from the resources a total production capacity of synthetic hydrocarbons; determining from the total production capacity, a number of elementary production units required for obtaining the total production capacity, each elementary production unit having an elementary production capacity between a 100 and a 1,000 barrels a day of synthetic hydrocarbons; building the number of elementary production units on the territory; transporting the carbonaceous material from the territory as far as the elementary production units; producing the synthetic hydrocarbons in the elementary production units from the transported carbonaceous material. | 2012-07-05 |
| 20120172461 | LOW PERMEABILITY COMPOSITE PROTON EXCHANGE MEMBRANE INCLUDING ORGANIC-INORGANIC HYBRID - A composite proton exchange membrane is made up of dispersed organized graphene in ion conducting polymer as a fuel barrier material. The composite proton exchange membrane includes an inorganic material of 0.001-10 wt % and an organic material of 99.999-90 wt %. The inorganic material is a graphene derivative with two-dimensional structure. The organic material includes a polymer material with sulfonic acid group. | 2012-07-05 |
| 20120172462 | Novel Interpenetrating Polymer Networks and Uses Thereof - Interpenetrating polymer networks comprising a first network of polymer A formed from monomers, at least one of which contains an aromatic group functionalized with a cation-exchange group, and a second network of polymer B formed from monomers, at least one of which contains a fluorinated group (R | 2012-07-05 |
| 20120172463 | METHOD FOR INHIBITING NITROSAMINE FORMATION IN ANION EXCHANGE RESINS - A method for inhibiting formation of nitrosamines and an anion exchange resin produced therefrom comprising providing an anion exchange resin with a nitrosating agent and applying an antioxidant to the resin to inhibit formation of nitrosamines on the anion exchange resin. | 2012-07-05 |
| 20120172464 | METHOD FOR INHIBITING NITROSAMINE FORMATION IN ANION EXCHANGE RESINS - A method for inhibiting formation of nitrosamines and an anion exchange resin produced therefrom comprising providing an anion exchange resin with a nitrosating agent and mixing a cation exchange resin with the anion exchange resin to inhibit formation of nitrosamines on the anion exchange resin. | 2012-07-05 |
| 20120172465 | ANION EXCHANGE RESINS HAVING CONTROLLED NITROSAMINE FORMATION - An anion exchange resin produced comprising providing an anion exchange resin with a nitrosating agent and applying an antioxidant to the resin to inhibit formation of nitrosamines on the anion exchange resin. | 2012-07-05 |
| 20120172466 | Extrusion of a Foamable Fluoropolymer - A process for making an extruded foamable composition is disclosed where the foamable composition includes a partially-crystalline melt processible perfluoropolymer and a foam nucleating package. The process makes a foamed product having uniform foam cell size at high speeds without loss of product quality. | 2012-07-05 |
| 20120172467 | FLAME RETARDANT SYSTEM - The invention relates to a flame retardant comprising
| 2012-07-05 |
| 20120172468 | EFFECTIVE USE OF MELAMINE SULFONATE CONDENSATE DISPERSANTS IN WALLBOARD CONTAINING FOAM - Effective use of dispersants in wallboard containing foam results from a method where stucco is mixed with a first dispersant and a first quantity of water to form a gypsum slurry. A soap is blended with a second dispersant and a second quantity of water to make a foam. Subsequently, the foam is combined with the slurry. Choice of different first and second dispersants and their relative amounts allows control of the size distribution of the foam bubbles in the slurry and the resulting voids in the gypsum core. Melamine sulfonate condensate and polycarboxylate dispersants are preferred dispersants. | 2012-07-05 |
| 20120172469 | Lightweight foamed fly ash based binders and method - A method of making a lightweight cementitious binder composition with improved compressive strength for products such as cementitious panels is disclosed. The method mixes fly ash, alkali metal salt of citric acid, alkali metal silicate, foaming agent for entraining air, water and in the preferred embodiment a foam stabilizing agent. Compositions which include fly ash selected from the group consisting of class C fly ash, class F fly ash and mixtures thereof, alkali metal salts of citric acid, alkali metal silicates, foaming agents, and preferably a foam stabilizer, such as polyvinyl alcohol, and do not require use of set retarders. Compositions containing class F fly ash can optionally contain Type III Portland cement. | 2012-07-05 |
| 20120172470 | POLYOL MIXTURES CONTAINING A 1,3- AND/OR 1,4-BIS(AMINOMETHYL)CYCLOHEXANE-INITIATED POLYOL AND AT LEAST ONE OF A METHYLENE BIS(CYCLOHEXYLAMINE)-INITIATED POLYOL AND A CYCLOHEXANEDIAMINE-INITIATED POLYOL, AND POLYURETHANES MADE THEREFROM - Polyether polyols are initiated 1,3- and/or 1,4-bis(aminomethyl)cyclohexane) and with either or both of a methylene bis(cyclohexylamine) compound and a cyclohexanediamine compound. The polyols are useful in making rigid polyurethane foams, especially foams for pour-in-place applications, where they give a good combination of low k-factor and short demold times. | 2012-07-05 |
| 20120172471 | SILICONE COMPOSITION SUITABLE FOR CROSS-LINKING BY DEHYDROCONDENSATION IN THE PRESENCE OF A NON-METAL CATALYST - A silicone composition is described that includes components having SiH/SiOH groupings and that can be polymerized/cross-linked by a dehydrocondensation reaction in the presence of a non-metal catalyst such as non-silylated, pentasubstituted guanidine, requiring a low activation temperature. | 2012-07-05 |
| 20120172472 | SILICONE COMPOSITION SUITABLE FOR CROSS-LINKING BY DEHYDROCONDENSATION IN THE PRESENCE OF A METAL CATALYST - A silicone composition is described that includes components having SiH/SiOH group and that can be polymerized/cross-linked by a dehydrocondensation reaction in the presence of a catalyst such as an iron-based complex or salt, requiring a low activation temperature. | 2012-07-05 |
| 20120172473 | SILICONE COMPOSITION WHICH IS CROSS-LINKABLE BY DEHYDROGENATIVE CONDENSATION IN THE PRESENCE OF A NON-METAL CATALYST - A silicone composition is described that includes components having SiH/SiOH groupings and that can be polymerized/cross-linked by a dehydrogenative condensation reaction in the presence of a non-metal tri- or tetrasubstituted non-silylated guanidine catalyst and requiring a low activation temperature. | 2012-07-05 |
| 20120172474 | Surface-Etched Etched Alumina/SiC Mini-Whisker Composite Material and Uses Thereof - A composition of matter comprising 0.01 to 35% by weight of Al | 2012-07-05 |
| 20120172475 | HIGHLY POROUS CERAMIC OXIDE AEROGELS HAVING IMPROVED FLEXIBILITY - Ceramic oxide aerogels incorporating periodically dispersed flexible linkages are provided. The flexible linkages impart greater flexibility than the native aerogels without those linkages, and have been shown to reduce or eliminate the need for supercritical CO | 2012-07-05 |
| 20120172476 | POLYURETHANE FOAMING PROCESSES AND FOAM PROPERTIES USING HALOGENATED OLEFIN BLOWING AGENT - The present invention relates to a method of producing more uniformly distributed polyurethane form using blowing agents. More particularly, the present invention relates to a method of producing more uniformly distributed polyurethane foam for an application in which flow of liquid polyurethane foam prior to solidification is important to its performance using a hydrochlorofluoroolefin (HCFO), such as 1233zd. | 2012-07-05 |
| 20120172477 | PHOTOCURABLE ADHESIVE COMPOSITION - A photocurable adhesive composition is provided, which comprises: a) a (meth)acrylate oligomer having one or more functional groups, b) a mono-functional monomer, a multi-functional monomer, or a mixture thereof, c) a photoinitiator, and d) a plasticizer having a refractive index of no less than 1.48. The photocurable adhesive composition of the present invention has good light transmittance, high refractive index and appropriate flowability and softness, and is easy to be coated and adhered. The photocurable adhesive composition of the present invention can be applied to optical products and simplify the manufacture processes, and provide adhesion property while retaining good reworkability and optical properties. | 2012-07-05 |
| 20120172478 | METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES - The invention provide a method for making silicone hydrogel based on the Lightstream Technology from a monomer mixture with a curing time of less than about 100 seconds. The present invention is also related to silicone hydrogel contact lenses made according to methods of the invention. | 2012-07-05 |
